TECX (Tectonic Therapeutic) Other Stockholders Equity: $-0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TECX Tectonic Therapeutic Inc TECX
14 GF Score
Price $33.98
! 3 Warning Signs
View Full Analysis

What is Tectonic Therapeutic Other Stockholders Equity?

Tectonic Therapeutic TECX -7.84% 14 Other Stockholders Equity is $-0.00 Mil as of Jun. 2026. GuruFocus rates TECX with a GF Score™ of 14/100. The stock has 3 warning signs investors should review.

Tectonic Therapeutic's Other Stockholders Equity for the quarter that ended in Jun. 2026 was $-0.00 Mil.

Tectonic Therapeutic's quarterly Other Stockholders Equity increased from Dec. 2025 ($-0.00 Mil) to Mar. 2026 ($0.00 Mil) but then declined from Mar. 2026 ($0.00 Mil) to Jun. 2026 ($-0.00 Mil).

Tectonic Therapeutic's annual Other Stockholders Equity increased from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($0.00 Mil) but then declined from Dec. 2024 ($0.00 Mil) to Dec. 2025 ($-0.00 Mil).

Tectonic Therapeutic Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Tectonic Therapeutic's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tectonic Therapeutic Other Stockholders Equity Chart

Tectonic Therapeutic Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
0.00 -0.00 0.00 0.00 -0.00

Tectonic Therapeutic Quarterly Data
Dec21 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.00 -0.00 0.00 -0.00
TECX
14GF Score
Tectonic Therapeutic Inc TECX
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tectonic Therapeutic Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of $-0.00 Mil mean?
Tectonic Therapeutic (TECX) has a Other Stockholders Equity of $-0.00 Mil as of Jun. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Tectonic Therapeutic and its competitors.
Is Tectonic Therapeutic's Other Stockholders Equity too high?
Tectonic Therapeutic's current Other Stockholders Equity is $-0.00 Mil. Overall, Tectonic Therapeutic has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Tectonic Therapeutic's Other Stockholders Equity compare to ZVRA and SPRY?
Tectonic Therapeutic's Other Stockholders Equity of $-0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Tectonic Therapeutic and its competitors. Tectonic Therapeutic's current Other Stockholders Equity is $-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tectonic Therapeutic stock overvalued right now?
Tectonic Therapeutic (TECX) has a current Other Stockholders Equity of $-0.00 Mil. The current Other Stockholders Equity is $-0.00 Mil. Tectonic Therapeutic's overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Tectonic Therapeutic (TECX), the current Other Stockholders Equity is $-0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tectonic Therapeutic Business Description

Address 490 Arsenal Way, Suite 210, Watertown, MA, USA, 02472
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.
14GF Score

Get the complete analysis for TECX

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$33.98
Price